BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 8808688)

  • 1. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
    Okuda K; Golub TR; Gilliland DG; Griffin JD
    Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
    Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
    Carlesso N; Griffin JD; Druker BJ
    Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways.
    Voss J; Posern G; Hannemann JR; Wiedemann LM; Turhan AG; Poirel H; Bernard OA; Adermann K; Kardinal C; Feller SM
    Oncogene; 2000 Mar; 19(13):1684-90. PubMed ID: 10763825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
    Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
    Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
    Danhauser-Riedl S; Warmuth M; Druker BJ; Emmerich B; Hallek M
    Cancer Res; 1996 Aug; 56(15):3589-96. PubMed ID: 8758931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors.
    Laneuville P; Timm M; Hudson AT
    Cancer Res; 1994 Mar; 54(5):1360-6. PubMed ID: 8118826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
    Perrotti D; Bonatti S; Trotta R; Martinez R; Skorski T; Salomoni P; Grassilli E; Lozzo RV; Cooper DR; Calabretta B
    EMBO J; 1998 Aug; 17(15):4442-55. PubMed ID: 9687511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
    Melo JV; Deininger MW
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):545-68, vii-viii. PubMed ID: 15271392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation of Ba/F3 cells and Rat-1 cells by ETV6/ARG.
    Iijima Y; Okuda K; Tojo A; Tri NK; Setoyama M; Sakaki Y; Asano S; Tokunaga K; Kruh GD; Sato Y
    Oncogene; 2002 Jun; 21(28):4374-83. PubMed ID: 12080468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
    Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
    Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the chronic myelogenous leukemia-associated p210bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line.
    Laneuville P; Heisterkamp N; Groffen J
    Oncogene; 1991 Feb; 6(2):275-82. PubMed ID: 1705688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
    Hoover RR; Gerlach MJ; Koh EY; Daley GQ
    Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
    Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
    J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in tyrosine phosphorylated proteins between cells expressing P210bcr/abl and P190bcr/abl.
    Nishimura J; Shibata K; Sadamura S; Takahira H; Hirata J; Umemura T; Nawata H; Okamura J
    Int J Hematol; 1992 Jun; 55(3):227-33. PubMed ID: 1379843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
    Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG
    Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.